Clinical Trial Update: Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 neoadjuvant study of camrelizumab plus apatinib and temozolomide in high-risk acral melanoma (NCT05512481) that i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Melanoma
• Melanoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Melanoma, Acral Melanoma | Phase 2 | Status: RECRUITING